Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial
The Lancet Oncology, May 2022
What happens to the preserved renal parenchyma after clamped partial nephrectomy?
European Urology, May 2022
Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial
Nature Medicine, February 2022
The Clinicopathologic and Molecular Landscape of Clear Cell Papillary Renal Cell Carcinoma: Implications in Diagnosis and Management
European Urology, Volume 79, Issue 4, April 2021, Pages 468-477
This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Privacy Policy.